EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, IOVA: Iovance Biotherapeutics Inc

27 Mar 26 15:59
LAST:

3.515

CHANGE:
 0.18		OPEN:
3.730		HIGH:
3.830		ASK:
6.500		VOLUME:
6.68M
CHG(%):
4.74		PREV:
3.690		LOW:
3.510		BID:
4.850		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Mar 263.7303.8303.5103.5156.68M
26 Mar 263.5803.8103.5203.6907.47M
25 Mar 263.7303.9693.6903.75010.58M
24 Mar 263.6003.6803.4303.62011.85M
23 Mar 263.7303.8103.6203.6309.01M
20 Mar 263.8703.9553.6103.69023.5M
19 Mar 263.7103.8903.6103.87010.48M
18 Mar 263.8104.0303.7603.77014.47M
17 Mar 264.0204.1183.8303.8909.75M
16 Mar 263.9924.1453.9104.04014.7M

PROFILE

Name:Iovance Biotherapeutics Inc
About:Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Sector:Healthcare
Industry:Biotechnology
Address:825 Industrial Road, San Carlos, CA, United States, 94070
Website:https://www.iovance.com
CUSIP:37182R102
CIK:0001425205
ISIN:US4622601007
FIGI:BBG000FTLBV7
LEI:549300220Z2GHH33XL82

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.52 
Forward P/E:-4.54 
PEG Ratio:0.52 
Price to Sales:2.95 
Price to Book:1.52 
Profit Margin:-1.61 
Operating Margin:-1.90 
Return on Assets:-0.27 
Return on Equity:-0.53 
EPS Ratio:-1.30 
Revenue:241.52M 
Shares:396.97M 
Market Cap:1.395B 

TECHNICAL INDICATORS

MA5:3.643.6%
MA10:3.756.6%
MA20:4.1217.3%
MA50:3.326.0%
MA100:2.8622.9%
MA200:2.5637.1%
RSI14:12.33 
WPR14:-100.00 
MTM14:-1.69
ROC14:-0.32 
ATR:0.35 
Week High:3.9712.9%
Week Low:3.432.5%
Month High:5.6360.2%
Month Low:3.4337.1%
Year High:5.6360.2%
Year Low:1.64114.5%
Volatility:60.66 

RECENT SPLITS

Date Ratio
26 Sep 20131-100
26 May 201023999-1000